Chief Executive Officer & Founder
Mr. Elam is a native of Silicon Valley who has been managing and advising healthcare and technology companies for more than 25 years.
Prior to co-founding Rezolute, Mr. Elam served in various senior leadership roles including as CEO of a European medical device company and as Head of the Pulmonary Business Unit at Nektar Therapeutics (NASDAQ: NKTR). During his tenure at Nektar, he was instrumental in reshaping the pipeline and streamlining the organization. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Pearl Therapeutics which was acquired in 2013 by AstraZeneca, for $1 billion.
Earlier in his career, Mr. Elam was CFO and co-founder of a web based IT platform company serving the electronics and healthcare industries where, in addition to managing finance and business development, he established operations in the US as well as throughout Asia.
In the 1990s, Mr. Elam was a corporate partner at Wilson Sonsini Goodrich & Rosati, where he advised domestic and ex-US healthcare and technology companies on various matters from debt and equity financings to cross-border transactions. His clients included emerging growth companies as well as mature corporations such as Genentech and Hewlett Packard. Notably, he negotiated the sale of Steve Jobs' company, Next, to Apple.
In addition to serving on the board of Rezolute, he also serves on the board of directors of Savara, Inc. (NASDAQ:SVRA) in Austin Texas and Softhale in Brussels, Belgium.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Head of Clinical Development
Prior to joining Rezolute Bio, Dr. Roberts directed clinical development at Fibrogen, Inc, where he helped successfully launch and execute the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease, concluding the largest Phase 3 program ever conducted in CKD anemia, and resulting in global NDA filings. During his tenure, Fibrogen achieved the largest biotech IPO in the previous 10 years. From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Metabolex, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, NASH, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy. He is an inventor or author on more than 20 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his medical degree Magna Cum Laude from Georgetown University. He completed residency in Internal Medicine and fellowship in Endocrinology at Stanford University, where he also now serves as Adjunct Associate Professor in the Division of Endocrinology.
Head of Scientific & Patient Affairs
Davelyn, a long-standing member of the patient advocacy group Congenital Hyperinsulinism International (CHI), joins the Rezolute team as Director of Scientific and Patient Affairs. Davelyn has served in various scientific and leadership capacities such as the President of the Board of Directors and Principal Investigator for the HI Global Registry. Davelyn’s breadth and depth of experience within the HI community will be a tremendous value in the execution of the RZ358 development program, and guide us in a direction that captures the needs of the patients and fosters collaborative relationships within the scientific community.
Vice President of Clinical Operations
Erin O’Boyle joined Rezolute with nearly 20 years of operational and management experience across all phases of development covering several therapeutic areas, including oncology, anemia, idiopathic pulmonary fibrosis and rare disease indications. Prior to joining Rezolute, Erin worked at Fibrogen where she led all clinical outsourcing and governance activities from 2013 to 2018. Erin successfully contracted and managed all vendors for each clinical department which supported their various programs. These programs ranged from the largest Phase 3 global anemia program ever conducted resulting in NDA filings to a small Phase 2 rare orphan pediatric study in Duchene Muscular Dystrophy.
Before transitioning to a clinical lead in both contracting and governance, Erin was the Head of Clinical Operations at Heron Therapeutics from 2005 to 2013. During her time at Heron Therapeutics, Erin successfully led a clinical program from Phase 1 up through NDA approval of SUSTOL® (granisetron), an extended-release injection, for subcutaneous use for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy. To date, this is the largest CINV program ever conducted.
Erin obtained a Bachelor’s degree in Biology from Stonehill College.
Vice President of Operations
Prior to joining Rezolute Inc. in 2016, Mr. Deperro spent the past two decades in technical operations leadership roles within large pharma, biotech, generics and in a contract development and manufacturing capacity. A Mechanical Engineer from the University of Notre Dame and former US Army Officer, Mike's early career focused on the implementation of manufacturing and research infrastructure in the US and Ireland for companies including Schering Plough, Merck and Novartis. Transitioning from pharmaceutical engineering to operations management, Mike directed the startup of a generic parenterals business unit, focusing on plant establishment, product development and support of product launch for global markets. As Director of Manufacturing at Alkermes, Mike's manufacturing operation supported global sales of Risperdal® Consta®, the launch of Vivitrol® and delivery of Phase 3 supplies for Bydureon®, all commercialized controlled release formulations utilizing injectable microsphere technologies. These commercial manufacturing operations encompassed polymerization, bulk sterile microsphere manufacture and aseptic fill finish for US and ROW markets. Most recently, as General Manager for GMP Operations at Bend Research, and Vice President of Operations for Agere Pharmaceuticals, Mike led specialized teams charged with the delivery of early phase clinical supplies for complex, poorly soluble molecules in fast-paced multi-client environments. Mike's passion for leadership, integration of complex technologies and a strong belief in positive patient outcomes provide a strong foundation for the development of sustainable operations at Rezolute.
Vice President of CMC
Michael Covarrubias joins Rezolute with over 30 years of biopharmaceutical development, manufacturing and CMC project management experiences. His work ranges from early stage through commercial product development, approval/launch and lifecycle management. He has worked at leading pharmaceutical companies on products that span a range of pediatric, rare disease, autoimmune and oncology indications. He brings specific experience with late-stage product development, product and process characterization, validation and global marketing authorization submissions and health authority engagement.
Vice President of Finance
Chris Milks joins Rezolute with over 18 years of biotech industry experience in finance and operations. Prior to joining Rezolute, Chris led the Clinical Finance group at FibroGen and also oversaw the Clinical Outsourcing group. Earlier in his career, Chris held positions of increasing responsibility at Gilead Sciences, mostly on the Financial, Planning and Analysis team. In that role, he supported all functions, from a finance perspective, at various times, including G&A, Sales and Marketing and Research and Development. Additionally, he also managed operations for the Access and Emerging Markets team working with partners internationally to increase access to its medicines in low and middle-income countries. Chris started his career at PriceWaterhouseCoopers while working toward his CPA.
Chris received his B.S. in Accounting from Santa Clara University and his M.B.A. from Haas School of Business at the University of California, Berkeley.
Head of Preclinical Development
Dr. Wang joined Rezolute, in 2014, with two decades biotech and pharmaceutical industry experience. She has broad knowledge and expertise in major aspects of small molecule and biologic therapeutic development ranging from target validation, drug discovery, preclinical development to clinical studies. She is experienced in managing core functional groups, overseeing contracted studies and leading multidisciplinary preclinical- and clinical-stage projects. Prior to joining Rezolute, Dr. Wang held positions with various responsibilities at Sugen (a subsidiary of Pharmacia acquired by Pfizer), Cymabay (formerly Metabolex), Takeda California, and NGM Bio. She has contributed to the development of two anticancer medicines that are currently on the market and is an author/inventor of over 40 publications and patents.
Dr. Wang received her Ph.D. in Physiology from University of Michigan and completed postdoctoral training in Cancer Research at Purdue University.
As the author and inventor of over 70 publications and patents, Dr. Mantripragada is a widely recognized expert in long-acting injectable therapies with demonstrated success in the discovery and development of a number of commercially marketed drugs, including Exparel®, Depocyt® and Xcience®. He designed and developed Locemia Solutions' intranasal glucagon, the first potential needle-free rescue treatment for severe hypoglycemia that was recently acquired by Eli Lilly and Company. Previous to co-founding Rezolute, Inc., Dr. Mantripragada served as Vice President and Head of Research & Development at PR Pharmaceuticals, Inc. Throughout his career, Dr. Mantripragada has served as an advisor to several companies specializing in diabetes, cell based therapies and cardiovascular diseases. His prior roles include Director of Research & Development at Guidant Corporation (now part of Abbott Vascular), as well as Director of Research & Development and Vice President of Scientific Development at SkyePharma (now Pacira Pharmaceuticals). Prior to transitioning to the pharmaceutical industry, Dr. Mantripragada was Assistant Professor of Biochemistry at the University of Virginia School of Medicine. His training includes a Ph.D. in Molecular Biophysics from the Indian Institute of Science and postdoctoral research at the Max Planck Institute for Biophysical Chemistry in Germany.
Head of Pharmaceutical Sciences
Understanding and targeting vascular biology in human disease has defined a sizable portion of Dr. Breit’s research career; he’s had the opportunity to study aberrant vascular endothelial growth factor (VEGF) regulation and signaling, the role of endothelial cell proliferation in pulmonary hypertension, as well as drug delivery to leaky blood vessels in solid cancers using targeted nanoparticles. He is currently leveraging his skill sets to advance Rezolute’s drug product portfolio through early and late stage drug development activities, while simultaneously growing the scientific understanding of current and future pipeline candidates. Dr. Breit received his Ph.D. from the College of Medicine at the University of South Alabama, and he completed his post-doctoral research at Roche Pharmaceuticals.